TABLE 1.
Characteristics of 2657 patients (291 prison based and 2366 community based) commencing hepatitis C treatment 2009–2012, by incarceration status
| Commenced treatment in prison (n=291) | Commenced treatment in community
|
||
|---|---|---|---|
| All (n=2366) | Matched sample (n=1137)a | ||
| Ageb | |||
| 20–29 years | 27 (9.3%) | 133 (5.6%) | 70 (6.2%) |
| 30–39 years | 136 (46.7%) | 773 (32.7%) | 513 (45.1%) |
| 40–49 years | 108 (37.1%) | 897 (37.9%) | 461 (40.6%) |
| >50 years | 20 (6.9%) | 563 (23.8%) | 93 (8.2%) |
|
| |||
| Sex | |||
| Male | 261 (89.7%) | 1714 (72.4%) | 995 (87.5%) |
| Female | 30 (10.3%) | 652 (27.6%) | 142 (12.5%) |
|
| |||
| Major HCV genotype | |||
| 1 or 4 | 115 (39.5%) | 872 (36.9%) | 461 (40.4%) |
| 2 | 16 (5.5%) | 134 (5.7%) | 55 (4.8%) |
| 3 | 160 (55.0%) | 1360 (57.5%) | 621 (54.6%) |
|
| |||
| Cirrhosisb | |||
| Diagnosed with cirrhosis | 8 (2.8%) | 277 (11.7%) | 40 (3.5%) |
| Not diagnosed with cirrhosis | 283 (97.3%) | 2089 (88.3%) | 1097 (96.5%) |
|
| |||
| Year treated | |||
| 2009 | 43 (14.8%) | 325 (13.7%) | 160 (14.1%) |
| 2010 | 108 (37.1%) | 767 (32.4%) | 385 (33.9%) |
| 2011 | 93 (32.0%) | 781 (33.0%) | 369 (32.5%) |
| 2012 | 47 (16.2%) | 493 (20.8%) | 223 (19.6%) |
|
| |||
| Treatment outcome (all genotypes) | |||
| SVR | 176 (60.5%) | 1425 (60.2%) | 715 (62.9%) |
| No response/Relapse | 35 (12.0%) | 478 (20.2%) | 196 (17.2%) |
| Unknown | 80 (27.5%) | 463 (19.6%) | 226 (19.9%) |
|
| |||
| Treatment outcome by genotype | |||
| Genotypes 1 and 4 | 115 (100%) | 872 (100%) | 461 (100%) |
| SVR | 56 (48.7%) | 439 (50.3%) | 256 (55.5%) |
| No response/Relapse | 22 (19.1%) | 275 (31.5%) | 122 (26.5%) |
| Unknown | 37 (32.2%) | 158 (18.1%) | 83 (18.0%) |
| Genotypes 2 and 3 | 176 (100%) | 1494 (100%) | 676 (100%) |
| SVR | 120 (68.2%) | 986 (66.0%) | 459 (67.9%) |
| No response/Relapse | 13 (7.4%) | 203 (13.6%) | 74 (10.9%) |
| Unknown | 43 (24.4%) | 305 (20.4%) | 143 (21.2%) |
a
Community-based sample were matched on age at treatment commencement, sex, treatment type, cirrhosis status at or within 30 days of treatment commencement and HCV genotype.
b
At treatment commencement.